IndustryCompany release
Mesoblast reports US$115M first full-year Ryoncil sales and advances four late-stage programmes
Mesoblast Ltd (MESO) · Tue 17 Nov 2026
Mesoblast says its mesenchymal stromal cell therapy earned US$115M in net revenue in FY2026, as the company progresses trials in back pain, heart failure, GvHD and Duchenne.
Mesoblast reported US$115M in net revenue for its 2026 financial year, the first full year of US sales of Ryoncil. The company describes the product as the only mesenchymal stromal cell therapy approved by the US Food and Drug Administration (FDA). The figures come from its full-year investor presentation.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Mesoblast Ltd ↗
Article written by VigiEye from the official source (Mesoblast Ltd). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
🇺🇸 Interpace Biosciences, Inc. (IDXG) · Tue 17 Nov 2026